

# Camille L GÃ©rard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5270799/publications.pdf>

Version: 2024-02-01

18  
papers

668  
citations

933447

10  
h-index

888059

17  
g-index

18  
all docs

18  
docs citations

18  
times ranked

800  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. <i>Cancer Cell</i> , 2022, 40, 114-116.	16.8	50
2	Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 1162.	3.7	9
3	Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology. <i>Endocrinology</i> , 2022, 163, .	2.8	21
4	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		6
5	A Process Mining Approach to Statistical Analysis: Application to a Real-World Advanced Melanoma Dataset. <i>Lecture Notes in Business Information Processing</i> , 2021, , 291-304.	1.0	4
6	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. <i>European Journal of Cancer</i> , 2021, 149, 37-48.	2.8	12
7	Turning tumors from cold to inflamed to improve immunotherapy response. <i>Cancer Treatment Reviews</i> , 2021, 101, 102227.	7.7	42
8	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. <i>Nature Medicine</i> , 2021, 27, 1362-1366.	30.7	70
9	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 836-847.	10.7	104
10	Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. <i>Nature Cancer</i> , 2021, 2, 693-708.	13.2	102
11	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma â€œ Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e343-e344.	10.7	2
12	Re-induction ipilimumab following acquired resistance to combination ipilimumab and antiâ€œPD-1 therapy. <i>European Journal of Cancer</i> , 2021, 153, 213-222.	2.8	7
13	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. <i>European Journal of Cancer</i> , 2021, 156, 149-163.	2.8	11
14	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1321-1337.	13.2	66
15	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320.	13.2	123
16	The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study. <i>Journal of Neuro-Oncology</i> , 2020, 146, 181-193.	2.9	18
17	Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8021.	4.1	3
18	Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage IIâ€œIII Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 2494-2502.	7.0	18